Abstract: Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4′, or nitro; R6 represents hydrogen or lower alkyl; and X represents methylene, R9 represents hydrogen, one of R7 and R8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

Abstract: Compounds of the general formula (I) are useful in the treatment and prevention of &bgr;3-related diseases including diabetes, obesity and hyperlipidemia wherein R1 is hydrogen, halogen, or hydroxyl; R2 is C1-4 alkyl or benzyl; R3 is OR, halogen, trifluoromethyl, C1-8 alkyl, lower acyl, NR4R4′, nitro, or cyano; R is hydrogen, C1-8 alkyl, benzyl group, or optionally substituted lower acyl; R4 and R4′ are each independently hydrogen, C1-4 alkyl, lower acyl, benzyl, or SO2R5; R5 is C1-4 alkyl or benzyl; W is oxygen, a secondary nitrogen atom (NH), or sulfur; and * represents an asymmetric carbon atom.

Abstract: Provided is a therapeutic agent comprising at least one member selected from the group consisting of an anticholinergic agent, a monoamine reuptake inhibitor, a lipase inhibitor, a selective serotonin reuptake inhibitor, insulin, an insulin secretagogue, biguanide, an &agr;-glucosidase inhibitor, an insulin resistance improving agent, a HMG-CoA reductase inhibitor, an anion exchange resin, a clofibrate type drug and a nicotinic acid type drug, and a compound having a &bgr;3 agonist activity. The &bgr;3-agonist has an activity of inhibiting dysuria. Further, when used together with a remedy for dysuria such as propiverine, oxybutynin hydrochloride or tolterodine, it exerts an enhanced anti-dysuria effect. When used together with an antiobestic agent such as sibutramine or orlistat, it exerts an enhanced antiobestic effect. When used together with an antidiabetic agent such as insulin, glibenclamide, acarbose or rosiglitazone, it exerts an enhanced antidiabetic effect.

Abstract: Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4, or nitro; R6 represents hydrogen or lower alkyl; and X represents nitrogen, R9 represents hydrogen, one of R7 and R8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

Abstract: Compounds represented by general formula (I) or their salts, having &bgr;3-adrenoceptor agonism and being efficacious when employed in drugs for treating and preventing diabetes, obesity, hyperlipemia, etc. wherein R represents hydrogen or methyl; R1 represents hydrogen, halogeno, hydroxy, benzyloxy, amino or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4 ′ or nitro (wherein R3 represents hydrogen, methyl, SO2R5, formyl or CONHR6′; R5 represents lower alkyl, benzyl or NR4R4′; R4 and R4′ may be the same or different and each represents hydrogen, lower alkyl or benzyl; and R6′ represents hydrogen or lower alkyl); R6 represents hydrogen or lower alkyl; n is 1 or 2; X represents secondary nitrogen, oxygen or sulfur; and when n is 1, then one of R7 and R8 represents hydrogen while another represents hydrogen, amino, acetylamino or hydroxy, or when n is 2, then R8 represents hydrogen while R7 represents hydrogen, amino, acetylamino or hydroxy.

Abstract: Compounds having a .beta.-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R.sup.1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R.sup.2 represents hydrogen, hydroxymethyl, NHR.sup.3, SO.sub.2 NR.sup.4 R.sup.4', or nitro; R.sup.6 represents hydrogen or lower alkyl; and X represents nitrogen, R.sup.9 represents hydrogen, one of R.sup.7 and R.sup.8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

Abstract: A viscosity of liquids is measured by inserting one end of a fine tube into one end of a tubular vessel sealed and maintained at a reduced pressure, while dipping the other end of the fine tube in a liquid to be measured, to cause the liquid to flow into the the vessel through the fine tube under the influence of a difference in pressure between both ends of the fine tube, detecting an internal pressure of the tubular vessel with a pressure sensor connected to the vessel to measure a change of an internal pressure of the vessel with passage of time and a change of a flow rate of the liquid passing through the fine tube with passage of time, and determining a viscosity of the liquid from the change of the internal pressure of the vessel and the change of the flow rate of the liquid. The pressure sensor is connected to the vessel by a device for piercing the other stopper and its output signals are fed to a computer through an A/D converter to calculate the viscosity of the liquid.